Share Price and Basic Stock Data
Last Updated: January 14, 2026, 8:27 pm
| PEG Ratio | 2.63 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bafna Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹297 Cr and a current price of ₹125 per share. The company has shown fluctuating revenue trends over recent quarters, with sales recorded at ₹21.96 Cr in September 2022, rising to ₹42.24 Cr by March 2023. However, sales declined to ₹28.44 Cr in December 2023, followed by a recovery to ₹41.40 Cr in March 2024. For the fiscal year ending March 2025, sales were ₹146 Cr, showing a slight decrease from ₹152 Cr in March 2024. This trend suggests a degree of volatility in revenue generation, which may be attributed to external market conditions or internal operational challenges. The company’s operating profit margin stood at 12.07%, reflecting the impact of fluctuating sales on overall profitability. The trailing twelve months (TTM) sales were ₹142 Cr, indicating a consistent revenue stream despite the short-term fluctuations.
Profitability and Efficiency Metrics
The profitability metrics for Bafna Pharmaceuticals exhibit a mixed performance. The reported net profit for the fiscal year ending March 2025 was ₹4 Cr, down from ₹7 Cr in March 2024. This decline is concerning, particularly given the company’s operating profit margin (OPM) of 12.07%, which is relatively low compared to industry averages. The interest coverage ratio (ICR) stood at a robust 15.48x, indicating a strong ability to meet interest obligations, which can be a positive factor in assessing financial health. Additionally, the return on equity (ROE) was recorded at 7.69%, suggesting moderate efficiency in generating profits from shareholders’ equity. However, the return on capital employed (ROCE) at 8.34% indicates that while the company is generating returns, they are below optimal levels compared to industry standards. The cash conversion cycle of 88 days reflects operational efficiency, as it measures the time taken to convert investments in inventory and other resources into cash flows.
Balance Sheet Strength and Financial Ratios
Bafna Pharmaceuticals’ balance sheet reveals a total asset base of ₹153 Cr and total liabilities of ₹161 Cr, indicating a slight imbalance that could raise concerns about financial stability. The company reported reserves of ₹68 Cr against borrowings of ₹32 Cr, suggesting a manageable debt level relative to its equity. The price-to-book value (P/BV) ratio of -0.49x is particularly alarming, as it indicates that the market value of the company’s equity is less than its book value, a situation often signaling investor pessimism. Furthermore, the debt-to-equity ratio appears favorable at a low level, providing a cushion against financial distress. The company’s operational efficiency is evidenced by a cash conversion cycle of 88 days, which is relatively low, allowing for quicker turnaround in cash flows. However, the declining trend in net profits and the current liabilities exceeding assets suggest a need for improved financial management strategies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bafna Pharmaceuticals indicates a strong promoter presence, with 75% of shares held by promoters as of March 2025, down from 90.01% in December 2022. This reduction may reflect a strategic move to attract institutional investors, as foreign institutional investors (FIIs) now hold 9.34% of the company, an increase from 0% in earlier periods. The public shareholding has also increased to 15.66%, indicating growing investor confidence and interest. The number of shareholders rose to 7,572, suggesting that the company is successfully engaging with a broader base of investors. Despite the positive shift in institutional interest, the high promoter holding could pose a risk of governance issues or reduced liquidity in shares. The lack of domestic institutional investors (DIIs) highlights a potential area for growth, as increasing institutional interest can enhance stock stability and investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Bafna Pharmaceuticals faces several risks and opportunities. The volatility in sales and declining net profits are significant concerns that could hinder growth prospects. The company’s ability to stabilize its revenue and improve profitability will be crucial in enhancing shareholder value. Additionally, the negative P/BV ratio suggests challenges in market perception, which may require strategic initiatives to rebuild investor confidence. On the positive side, the strong interest coverage ratio and manageable debt levels provide a solid foundation for operational resilience. The increasing FII stake indicates a potential turnaround, provided the company can leverage this interest to implement growth strategies effectively. In summary, while Bafna Pharmaceuticals shows promise in certain areas, it must address its profitability challenges and financial management to ensure sustainable growth in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,219.41 Cr | 1,122.07 | 52.62 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.96 | 34.22 | 42.24 | 41.95 | 40.68 | 28.44 | 41.40 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 | 35.47 |
| Expenses | 19.42 | 31.18 | 34.62 | 35.66 | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 | 31.19 |
| Operating Profit | 2.54 | 3.04 | 7.62 | 6.29 | 4.01 | -2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 | 4.28 |
| OPM % | 11.57% | 8.88% | 18.04% | 14.99% | 9.86% | -7.28% | 6.98% | 3.63% | 9.40% | 9.22% | 7.96% | 14.64% | 12.07% |
| Other Income | 0.64 | 1.93 | 0.26 | 1.87 | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.18 | -0.76 | 0.60 | 1.18 |
| Interest | 0.45 | 0.58 | 0.70 | 0.60 | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 | 0.86 |
| Depreciation | 1.12 | 1.40 | 1.53 | 1.21 | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 | 1.47 |
| Profit before tax | 1.61 | 2.99 | 5.65 | 6.35 | 2.49 | -2.94 | 1.46 | -0.72 | 2.61 | 0.94 | 1.31 | 3.39 | 3.13 |
| Tax % | 0.00% | 0.00% | 4.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 1.61 | 3.00 | 5.37 | 6.35 | 2.48 | -2.94 | 1.46 | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 |
| EPS in Rs | 0.68 | 1.27 | 2.27 | 2.68 | 1.05 | -1.24 | 0.62 | -0.30 | 1.11 | 0.40 | 0.55 | 1.43 | 1.32 |
Last Updated: January 2, 2026, 8:31 am
Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 35.47 Cr.. The value appears strong and on an upward trend. It has increased from 34.62 Cr. (Jun 2025) to 35.47 Cr., marking an increase of 0.85 Cr..
- For Expenses, as of Sep 2025, the value is 31.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.55 Cr. (Jun 2025) to 31.19 Cr., marking an increase of 1.64 Cr..
- For Operating Profit, as of Sep 2025, the value is 4.28 Cr.. The value appears to be declining and may need further review. It has decreased from 5.07 Cr. (Jun 2025) to 4.28 Cr., marking a decrease of 0.79 Cr..
- For OPM %, as of Sep 2025, the value is 12.07%. The value appears to be declining and may need further review. It has decreased from 14.64% (Jun 2025) to 12.07%, marking a decrease of 2.57%.
- For Other Income, as of Sep 2025, the value is 1.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.60 Cr. (Jun 2025) to 1.18 Cr., marking an increase of 0.58 Cr..
- For Interest, as of Sep 2025, the value is 0.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.91 Cr. (Jun 2025) to 0.86 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 1.47 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.37 Cr. (Jun 2025) to 1.47 Cr., marking an increase of 0.10 Cr..
- For Profit before tax, as of Sep 2025, the value is 3.13 Cr.. The value appears to be declining and may need further review. It has decreased from 3.39 Cr. (Jun 2025) to 3.13 Cr., marking a decrease of 0.26 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 3.12 Cr.. The value appears to be declining and may need further review. It has decreased from 3.39 Cr. (Jun 2025) to 3.12 Cr., marking a decrease of 0.27 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.32. The value appears to be declining and may need further review. It has decreased from 1.43 (Jun 2025) to 1.32, marking a decrease of 0.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 142 |
| Expenses | 156 | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 127 |
| Operating Profit | 21 | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 11 | 16 |
| OPM % | 12% | -16% | 3% | -8% | -77% | -30% | 3% | 14% | 14% | 14% | 7% | 8% | 11% |
| Other Income | 1 | 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 1 | 1 |
| Interest | 12 | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 8 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 2 | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 4 | 9 |
| Tax % | 40% | -0% | -3% | -4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | 0% | |
| Net Profit | 1 | 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 4 | 9 |
| EPS in Rs | 0.72 | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 3.70 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -300.00% | -50.00% | 11.11% | -25.00% | -25.00% | 124.00% | -16.67% | 120.00% | -36.36% | -42.86% |
| Change in YoY Net Profit Growth (%) | 0.00% | -800.00% | 250.00% | 61.11% | -36.11% | 0.00% | 149.00% | -140.67% | 136.67% | -156.36% | -6.49% |
Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 28% |
| 3 Years: | 20% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 40% |
| 3 Years: | -5% |
| TTM: | 1498% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 34% |
| 3 Years: | -4% |
| 1 Year: | 25% |
| Return on Equity | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 12:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 50 | 53 | 41 | 26 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 61 | 68 |
| Borrowings | 99 | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 32 |
| Other Liabilities | 54 | 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 37 |
| Total Liabilities | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
| Fixed Assets | 63 | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 65 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 7 | 15 |
| Investments | 1 | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 158 | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 81 |
| Total Assets | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 7.00 Cr..
- For Borrowings, as of Sep 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 28.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be improving (decreasing). It has decreased from 40.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 161.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 6.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 6.00 Cr..
- For Total Assets, as of Sep 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
Notably, the Reserves (68.00 Cr.) exceed the Borrowings (32.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -78.00 | -80.00 | -77.00 | -87.00 | -82.00 | -59.00 | -2.00 | -5.00 | 1.00 | -7.00 | -13.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192 | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 |
| Inventory Days | 78 | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 |
| Days Payable | 116 | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 |
| Cash Conversion Cycle | 155 | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 | 88 |
| Working Capital Days | 41 | 56 | 125 | -36 | -108 | -210 | 89 | 121 | 123 | 104 | 92 | 74 |
| ROCE % | 9% | -13% | -0% | -6% | -35% | -21% | -3% | 10% | 11% | 16% | 9% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Diluted EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Cash EPS (Rs.) | -89.52 | -6.29 | -5.47 | -8.17 | -5.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Revenue From Operations / Share (Rs.) | 179.54 | 18.33 | 19.94 | 34.82 | 45.73 |
| PBDIT / Share (Rs.) | 6.25 | -5.36 | -1.61 | -2.50 | 1.34 |
| PBIT / Share (Rs.) | -7.56 | -6.83 | -3.29 | -4.76 | -1.27 |
| PBT / Share (Rs.) | -103.32 | -7.30 | -6.22 | -10.91 | -8.21 |
| Net Profit / Share (Rs.) | -103.32 | -7.76 | -7.15 | -10.43 | -8.12 |
| NP After MI And SOA / Share (Rs.) | -104.54 | -7.98 | -7.07 | -10.23 | -7.52 |
| PBDIT Margin (%) | 3.48 | -29.26 | -8.05 | -7.18 | 2.92 |
| PBIT Margin (%) | -4.20 | -37.28 | -16.47 | -13.68 | -2.76 |
| PBT Margin (%) | -57.54 | -39.86 | -31.19 | -31.34 | -17.95 |
| Net Profit Margin (%) | -57.54 | -42.32 | -35.84 | -29.95 | -17.74 |
| NP After MI And SOA Margin (%) | -58.22 | -43.52 | -35.48 | -29.38 | -16.44 |
| Return on Networth / Equity (%) | 0.00 | -99.01 | -44.12 | -44.73 | -24.28 |
| Return on Capital Employeed (%) | -3.29 | -33.22 | -9.90 | -9.17 | -2.41 |
| Return On Assets (%) | -34.67 | -15.79 | -12.09 | -10.70 | -7.27 |
| Long Term Debt / Equity (X) | -0.71 | 1.21 | 0.61 | 0.91 | 0.60 |
| Total Debt / Equity (X) | -0.71 | 2.43 | 1.23 | 1.93 | 1.39 |
| Asset Turnover Ratio (%) | 0.44 | 0.33 | 0.30 | 0.36 | 0.44 |
| Current Ratio (X) | 2.11 | 0.68 | 0.81 | 0.94 | 1.29 |
| Quick Ratio (X) | 1.44 | 0.55 | 0.63 | 0.74 | 1.11 |
| Inventory Turnover Ratio (X) | 2.24 | 2.66 | 1.55 | 0.89 | 0.97 |
| Interest Coverage Ratio (X) | 15.48 | -5.97 | -0.54 | -0.40 | 0.19 |
| Interest Coverage Ratio (Post Tax) (X) | -18.72 | -8.10 | -1.44 | -0.69 | -0.16 |
| Enterprise Value (Cr.) | -3.29 | 69.21 | 109.10 | 134.30 | 133.55 |
| EV / Net Operating Revenue (X) | -0.07 | 1.60 | 2.31 | 2.07 | 1.57 |
| EV / EBITDA (X) | -2.22 | -5.45 | -28.71 | -28.76 | 53.52 |
| MarketCap / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| Price / BV (X) | -0.49 | 1.36 | 1.75 | 1.29 | 0.96 |
| Price / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| EarningsYield | -11.80 | -0.72 | -0.25 | -0.34 | -0.25 |
After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
- For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
- For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
- For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
- For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
- For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
- For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
- For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
- For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
- For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
- For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
- For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
- For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
- For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
- For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
- For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
- For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
- For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
- For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
- For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
- For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
- For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
- For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
- Net Profit Margin: -57.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -3.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -18.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.44
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.6 (Industry average Stock P/E: 52.62)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -57.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bafna Towers, Chennai (Madras) Tamil Nadu 600001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. S Hemalatha | Whole Time Director |
| Mr. Vinayak Dinesh Dendukuri | Whole Time Director |
| Mr. Upendar Mekala Reddy | Non Exe.Non Ind.Director |
| Mrs. Akila C Raju | Non Exe.Non Ind.Director |
| Ms. R Chitra | Ind. Non-Executive Director |
| Mr. Navin Kumar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's intrinsic value (as of 15 January 2026) is ₹69.27 which is 45.88% lower the current market price of ₹128.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹302 Cr. market cap, FY2025-2026 high/low of ₹205/67.8, reserves of ₹68 Cr, and liabilities of ₹161 Cr.
What is the Market Cap of Bafna Pharmaceuticals Ltd?
The Market Cap of Bafna Pharmaceuticals Ltd is 302 Cr..
What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 15 January 2026?
The current stock price of Bafna Pharmaceuticals Ltd as on 15 January 2026 is ₹128.
What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bafna Pharmaceuticals Ltd stocks is ₹205/67.8.
What is the Stock P/E of Bafna Pharmaceuticals Ltd?
The Stock P/E of Bafna Pharmaceuticals Ltd is 28.6.
What is the Book Value of Bafna Pharmaceuticals Ltd?
The Book Value of Bafna Pharmaceuticals Ltd is 38.6.
What is the Dividend Yield of Bafna Pharmaceuticals Ltd?
The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Bafna Pharmaceuticals Ltd?
The ROCE of Bafna Pharmaceuticals Ltd is 8.34 %.
What is the ROE of Bafna Pharmaceuticals Ltd?
The ROE of Bafna Pharmaceuticals Ltd is 7.69 %.
What is the Face Value of Bafna Pharmaceuticals Ltd?
The Face Value of Bafna Pharmaceuticals Ltd is 10.0.